The US$11.7bn CSL Vifor deal could be a match made in heaven
It has been over two months since the CSL Vifor deal was completed. CSL held an investor briefing this morning,…
3 best performing ASX shares in the week of 10 October 2022
The 3 best performing ASX shares in the week of 3 October 2022 The 3 best performing ASX shares of…
2 ASX Technology stocks that are set to recover
When the market bottoms, which ASX Technology stocks should you buy? Our own Stuart Roberts spoke to Ausbiz about…
Domino’s Pizza investors are shrugging off inflation fears
Why are Domino’s Pizza Enterprises (ASX:DMP) shares up over 10% since Wednesday? There’s no news out of the company, but…
When buying opportunities knock, you better open the door
Stock markets have come down to the point that we are seeing more and more buying opportunities. Why are we…
Is Elmo Software getting a better takeover offer?
Elmo Software (ASX: ELO) has gone into a trading halt this morning pending news of ‘possible corporate activity’. This is…
Aldoro Resources unveils a solid maiden JORC Resource estimate
Rubidium and lithium explorer Aldoro Resources (ASX:ARN) gave its shareholders a hint of just how much lithium and rubidium there…
Baby Bunting started FY23 with a margin downgrade
Baby Bunting (ASX:BBN) shareholders punished the company today for revealing a hit to its gross margins. Despite recording sales growth,…
3 best performing ASX shares in the week of 3 October 2022
The 3 best performing ASX shares in the week of 3 October 2022 The 3 best performing ASX shares of…
Sheffield Resources is going ahead with Stage 1 of Thunderbird
Sheffield Resources (ASX:SFX) has announced its Thunderbird Mineral Sands Project (at least Stage 1 of the project) is going ahead,…
Another Appen trading update, another downgrade … stock crashes 18%
Every Appen (ASX:APX) ASX trading update or results in the past couple of years has been negatively received by investors.…
Why people hate Flight Centre so much…
Why do people hate Flight Centre so much … Flight Centre (ASX:FLT) has a bad reputation despite its long track…
Paradigm Biopharmaceuticals’ Phase 2 clinical trial is a success…so far
One of the best pieces of news shareholders in a biotech stock can receive is successful Phase II clinical trial…
ASX lithium stocks have delivered stellar results this week!
Lithium has been the best space to be in on the ASX this week. Although the markets are dour, there…
Iress scares investors with big CY22 profit downgrade
Iress (ASX:IRE) shares fell more than 15% this morning thanks to the company downgrading its profit guidance. The company said…